Summary statistics - qualitative results

EQA round: IDDM2/26 - Type 1 Autoimmune Diabetes

Deadline: 16.10.2026

Setup: groups - M (measurement principle)

AV = assigned value
CVP = consensus of all participants
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV		Frequency of the results N_{tot}	N_{rel} [%]	Result	Success N_{eva}	N_{suc}	S_{rel} [%]
(472) **anti-GAD**			36			36	35	97
Sample A			36			36	36	100
(2) EIA methods	CVP	>>>	24	67	Positive			
(3) RIA, IRMA	CVP	>>>	2	5,6	Positive			
(4) Luminiscence	CVP	>>>	7	19	Positive			
(99) Another measurement principle	CVP	>>>	3	8,3	Positive			
Sample B			36			36	35	97
(2) EIA methods	CVP	>>>	23	64	Negative			
			1	2,8	Positive			
(3) RIA, IRMA	CVP	>>>	2	5,6	Negative			
(4) Luminiscence	CVP	>>>	7	19	Negative			
(99) Another measurement principle	CVP	>>>	3	8,3	Negative			
(474) **anti-IA-2**			34			34	31	91
Sample A			34			34	33	97
(2) EIA methods	CVP	>>>	22	65	Negative			
			1	2,9	Positive			
(3) RIA, IRMA	CVP	>>>	1	2,9	Negative			
(4) Luminiscence	CVP	>>>	7	21	Negative			
(99) Another measurement principle	CVP	>>>	3	8,8	Negative			
Sample B			34			34	31	91
(2) EIA methods	CVP	>>>	21	62	Negative			
			2	5,9	Positive			
(3) RIA, IRMA	CVP	>>>	1	2,9	Negative			
(4) Luminiscence			1	2,9	Not specified			
	CVP	>>>	6	18	Negative			
(99) Another measurement principle	CVP	>>>	3	8,8	Negative			